# Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo

> **NCT02632812** · PHASE1 · COMPLETED · sponsor: **Biolab Sanus Farmaceutica** · enrollment: 24 (actual)

## Conditions studied

- Gastrointestinal Lesions

## Interventions

- **DRUG:** Rebamipide effervescent granules
- **DRUG:** Placebo effervescent granules
- **DRUG:** Naproxen tablet

## Key facts

- **NCT ID:** NCT02632812
- **Lead sponsor:** Biolab Sanus Farmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632812, "Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02632812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*